Evotec forms collaboration with Petra Pharma on INDiGO platform

Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-forms-collaboration-with-petra-pharma-on-indigo-platform-5667

Weiterlesen

Ad hoc: Evotec AG plans conversion into European Company (SE)

Evotec AG today decided to begin preparations for legal conversion of the Company into a European Company (Societas Europaea, SE). The proposal, which has already been approved by the Supervisory Board, will be put to a vote at this year’s Annual General Meeting on 20 June 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-plans-conversion-into-european-company-se-5663

Weiterlesen

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic

Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-launches-indigor-a-unique-integrated-drug-development-solution-for-accelerating-early-drug-candidates-into-the-clinic-5660

Weiterlesen

Evotec AG to report fiscal year 2017 results on 28 March 2018

Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-fiscal-year-2017-results-on-28-march-2018-5657

Weiterlesen

Ad hoc: Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Evotec AG today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-sanofi-in-exclusive-talks-to-create-an-evotec-led-infectious-disease-open-innovation-rd-platform-5650

Weiterlesen

Evotec and Sanofi in exclusive talks to create an Evotec-led infectious disease open innovation R&D platform

Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-in-exclusive-talks-to-create-an-evotec-led-infectious-disease-open-innovation-rd-platform-5646

Weiterlesen

Novo Holdings announce launch of “REPAIR” and formation of Scientific Selection Board

According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/novo-holdings-announce-launch-of-repair-and-formation-of-scientific-selection-board-5641

Weiterlesen

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party alliance signed in August 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-achieve-first-milestone-in-immuno-oncology-alliance-with-sanofi-5635

Weiterlesen